|
Progress in long-acting Agents for HIV Treatment & PrEP:
ViiV healthcare program: Focus on Cabotegravir Long-Acting Injection; Future ViiV LA programs at HIV-DART
|
|
|
HIV DART Dec 10 2020
Bill Spreen, PharmD
Cabotegravir Medicine Development leader
ViiV Healthcare
![1215201](../images/121520/121520-2/1215201.gif)
![1215202](../images/121520/121520-2/1215202.gif)
![1215203](../images/121520/121520-2/1215203.gif)
![1215204](../images/121520/121520-2/1215204.gif)
![1215205](../images/121520/121520-2/1215205.gif)
![1215206](../images/121520/121520-2/1215206.gif)
![1215207](../images/121520/121520-2/1215207.gif)
![1215208](../images/121520/121520-2/1215208.gif)
![12152010](../images/121520/121520-2/12152010.gif)
|
|
|
|
|
|
|